News

Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea
Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...
Pharmaceutical Technology on MSN9h
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...
Zacks Investment Research on MSN2d
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Bayer AG BAYRY announced that it has initiated a phase I study, which is evaluating its investigational highly selective ...
Manchester Journal14d
Ounce of Prevention | Using aspirin to prevent pre-eclampsia and related problems
Ounce of Prevention is a weekly column which presents recommendations for preventative services derived from The United States Preventive Services Task Force (USPSTF). Each column begins with the name ...
Pharmabiz25d
UK MHRA grants marketing authorization to Bayer’s acoramidis to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy
to treat adult patients with cardiomyopathy (damage to the heart muscle) caused by variant or wild-type transthyretin amyloidosis (ATTR-CM). The new marketing authorisation was granted on 24th April, ...